Takeda has reported site-specific responses among patients with 

 in the scalp, nails, palms and soles with zasocitinib, an investigational once-daily oral tyrosine kinase 2 (TYK2) inhibitor, in 2 phase 3 trials.¹

LATITUDE PsO 3001 and 3002 enrolled 693 and 1,108 adults with moderate-to-severe plaque psoriasis and compared zasocitinib with placebo and apremilast.¹ The 

 has accepted the New Drug Application under Priority Review, with a target action date slated for the first quarter of 2027, Takeda announced in September 2026.¹

At Week 16, 77% of those in 3001 and 74% in 3002 attained scalp-specific Physician Global Assessment (ssPGA) scores of 0 or 1, compared with 7% and 13% with placebo (

 < .001).¹˒² The Nail Psoriasis Severity Index (NAPSI) least-squares mean shift from the point of baseline was -7.1 in 3001 and -8.6 in 3002 (

 < .001 vs placebo).¹˒² Hands and/or feet Physician Global Assessment (hfPGA) scores of 0 or 1 occurred in 71% and 69% with zasocitinib, compared with 22% and 10% with placebo, in a secondary endpoint not controlled for multiplicity.¹

In 3002, 17% of patients reached Psoriasis Area and Severity Index 75 (PASI 75) at week 4 with zasocitinib, compared with 4% with placebo (

 < .001).¹ Takeda also reported skin clearance increasing through weeks 24 and 52, with no new safety signals.¹ The open-label LATITUDE PsO 3003 study, which enrolled about 2,100 participants, is evaluating long-term safety, tolerability and efficacy.¹

Raj Chovatiya, MD, PhD, a board-certified dermatologist and associate professor at Rosalind Franklin University Chicago Medical School, also founded and directs the Center for Medical Dermatology + Immunology Research in Chicago. In the following Q&A interview discussion, Chovatiya shares his perspective on special site involvement, speed of response and once-daily dosing with zasocitinib:

HCPLive: Why are the scalp, nails, palms and soles particularly challenging areas from both a treatment and cosmetic perspective?

 In psoriasis, we talk about special sites, and what really makes them special is, number one, they seem to potentially be slightly more difficult in terms of drug penetration. So we've always wondered if you had the right type of targeting agent, could you potentially hit better efficacy? And two, individuals who may have involvement of these areas can have relatively limited extent, but they oftentimes feel the same degree of burden as somebody who might have more traditional plaque psoriasis from head to toe.

If you think about your scalp being a part of the head and neck region that you have to go about every single day, talking to folks, having people looking at you, when you think about your hands, shaking hands, going out there doing your work and day-to-day functioning, thinking about your nails, even thinking about the genital region as well, all of these are special in the sense that they're often associated with undue burden for our patients. So it's particularly exciting, beyond some of the top-line data we've seen, that zasocitinib can result in a high degree of clearance in these areas too. And I think the scientific question that's very interesting is, now with more and more small-molecule options coming about in psoriasis, might there be a pathogenic reason why we see efficacy there compared to biologic therapies?

That question isn't really known, but we wonder if there's going to be a root reason why we could potentially have better effect there, or even a target standpoint. One of the theoretical ideas with TYK2 inhibition has been, given its role in other elements of the immune system signaling pathway, could it potentially result in some different degrees of clearance in some of these sites too? And I think that's really what the next generation of research is setting us up for, as long as we have newer therapeutic options.

: With about 70% of patients achieving clear or almost clear skin at week 16, how quickly might patients see a visible difference?

 One of the nice things about the data cuts we've seen from zasocitinib so far is that it definitely doesn't appear to be slow. I think our patients are going to start seeing meaningful differences pretty early, and it seems like many of these results also continue to improve, potentially even beyond the primary period of our examination as we enter longer phases of this study. Compared to the way we've felt about oral therapies prior, and particularly in the case of our more first-generation TYK2 inhibitors, I think we're going to be able to have a reasonable discussion and balance of speed, effectiveness, as well as long-term effectiveness and durability overall.

: How might a once-daily oral option like zasocitinib change the conversation around managing visible psoriasis?

I think if somebody can get over the idea of having to use something beyond a cream, then a once-daily option you can take orally resonates with the way we've all thought about medications all of our lives. Whether you think about antibiotics or analgesics or cold medication, they're all essentially once-daily medications that you take for varying degrees of time. In this case, this one would be more of a chronic medication. But I think the idea of something you just have to take once a day as a pill continues to be an important piece in the psyche of just human beings when thinking about medications overall.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Takeda Pharmaceutical Company Limited. U.S. FDA accepts new drug application under priority review for Takeda's zasocitinib in moderate-to-severe plaque psoriasis, with potential to redefine oral treatment expectations. Published September 14, 2026. Accessed September 21, 2026. 

https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/

Armstrong AW, et al. Zasocitinib, a once-daily oral TYK2 inhibitor, demonstrates efficacy at high impact sites in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002). Presented at: 2026 American Academy of Dermatology Innovation Academy; July 16, 2026; New York, NY.

Articles

Takeda’s investigational once-daily oral TYK2 inhibitor zasocitinib demonstrated robust special-site efficacy in phase 3 plaque psoriasis, with high rates of scalp clearance and meaningful improvements in nail disease, plus strong hands/feet responses. Onset appeared rapid, with early PASI 75 separation by week 4 and continued gains through weeks 24 and 52, without new safety signals. FDA accepted the NDA under Priority Review with an action date anticipated in Q1 2027. Long-term safety and durability are being assessed in a large open-label extension.

Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Q&A: Zasocitinib Response in the Scalp, Nails, Palms and Soles

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

) specialists are increasingly candid about a widening gap between how pivotal trials are built and the patients they actually treat, a tension that shaped a recent clinical forum on the 4 therapeutic pathways now available for PAH. Several developments have reshaped access this year: multiple manufacturers began marketing generic macitentan starting in 2025, a transition panelists described as one of the most disruptive their prior-authorization teams have handled

, even as the fixed-dose macitentan-tadalafil combination’s 90-day free-drug program has been credited elsewhere with helping practices start upfront dual oral therapy without delay.

 Separately, the European Respiratory Society formally added the activin signaling inhibitor sotatercept as a strong add-on recommendation for intermediate- and high-risk patients in a September 2026 guideline update.

Against that backdrop, a panel of pulmonary hypertension specialists gathered for a case-based dinner discussion moderated by Vallerie McLaughlin, MD, who directs the pulmonary hypertension program at the University of Michigan and has practiced in the field for nearly 30 years. The panel included experts from University of Pennsylvania and other community and academic PH specialists.

The conversation arrived at a moment when panelists increasingly described a gap between how PAH trials are constructed and the patients they see in clinic, and between formal risk-stratification algorithms and the “dirty PAH” patients whose comorbid lung or left-heart disease rarely fits cleanly into either. That tension shaped nearly every clinical question the panel worked through, from first-line drug selection to how newer disease-modifying options belong in a treatment sequence that, a generation ago, offered almost nothing.

How Does ‘Dirty PAH’ Complicate Guideline-Based Risk Stratification?

Panelists repeatedly returned to what several called “dirty PAH”—patients with PAH complicated by interstitial lung disease, chronic obstructive pulmonary disease (COPD), or left-heart diastolic dysfunction who rarely match pivotal-trial enrollment criteria. 

McLaughlin put the broader problem directly: “I’ll use clean PAH patients with 25 inclusion criteria and 50 exclusion criteria, and the majority of patients that we see in clinic that we’re making these decisions on, that we’re applying these guidelines to would not have met all of those inclusion and exclusion criteria.” 

The panel split on risk-assessment tools, with some defaulting to REVEAL because it is built into their EMR and others preferring the 4-strata ESC/ERS framework, several using both when the tools disagree. Six-minute walk distance and NT-proBNP drew open skepticism from multiple panelists, who argued neither reliably drives escalation decisions alone and that trends in oxygen saturation, heart rate response, and right ventricular function on echocardiography are more informative—a debate panelists said is growing more complicated as substantial GLP-1-associated weight loss shifts natriuretic peptide levels independent of right heart function.

How Did Insurance Access, Drug Sequencing Divide the Panel?

On drug sequencing more broadly, panelists described starting most non-high-risk patients on upfront dual combination therapy, typically an endothelin receptor antagonist plus a PDE5 inhibitor, often via the fixed-dose macitentan-tadalafil tablet, though several noted they still stagger the 2 components by a week or 2 in practice even when both are approved together. Patients with overlapping lung disease drove a different calculus: several panelists said they reach for inhaled prostacyclin therapy in that population because it can be titrated faster than oral formulations, reserving parenteral therapy for patients too sick to wait. Insurance access surfaced as a recurring frustration across drug classes, not just newer therapies—panelists described wide inconsistency in which agents get approved and when, including 1 physician denied tadalafil coverage for a newly diagnosed, severely ill patient the same day a costlier add-on therapy was approved for a different patient. Multiple panelists credited dedicated pharmacy and prior-authorization staff, rather than any single clinical strategy, as the single biggest factor in getting patients onto guideline-recommended combination therapy.

Generic Opsumit Availability. Drugs.com. Accessed September 21, 2026. https://www.drugs.com/availability/generic-opsumit.html

PAH in 2026: Algorithm Shifts and Real-World Gaps. HCPLive. Accessed September 21, 2026. https://hcplive.com/view/pah-2026-algorithm-shifts-prostacyclin-new-role-real-world-gaps

ERS Adds Sotatercept to Pulmonary Arterial Hypertension Treatment Guidelines. Pharmacy Times. Published September 16, 2026. Accessed September 21, 2026. https://pharmacytimes.com/view/ers-adds-sotatercept-to-pah-treatment-guidelines

Pulmonary arterial hypertension management is being reframed by real-world complexity, payer friction, and evolving guidance across four therapeutic pathways. Generic macitentan availability in 2025 has disrupted prior-authorization workflows, while fixed-dose macitentan–tadalafil access programs can accelerate upfront dual oral therapy. A 2026 ERS update strongly endorses sotatercept as add-on therapy for intermediate- and high-risk patients. Clinicians emphasized “dirty PAH” phenotypes that diverge from trial populations, complicating risk stratification and sequencing decisions, particularly in patients with overlapping lung or left-heart disease.

Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

Kazem Rahimi, MD, is a professor of cardiovascular medicine and population health and the director of the Deep Medicine program at the University of Oxford.

 medications resulted in consistent cardiovascular disease risk reduction and absolute benefits across patients with various levels of cardiovascular risk, according to a recent IPD analysis.

Blood Pressure Treatment Shows Consistent Benefit Across Cardiovascular Risk Spectrum

European Society of Cardiology (ESC) Congress 2026

 in Munich, Germany, by Kazem Rahimi, MD, professor of cardiovascular medicine and population health and director of the Deep Medicine program at the University of Oxford. The study follows Rahimi’s previous publication of a meta-analysis of long-term antihypertensive treatment on cardiovascular risk.

“There have been previous studies that have tried to look at this, but they were essentially smaller in sample size,” Rahimi told 

 in an interview. “As a consequence of that, we were not confident as to whether treatment works in low-risk individuals.”

The previous study was an IPD meta-analysis of 51 randomized trials of blood pressure (BP)-lowering drugs versus placebo, active control, or differing intensities. Trials were also required to have ≥1000 patient-years per arm. These trials were also utilized for the present study, which was conducted in the same format. Among the included trials were 20 placebo-controlled studies, 23 active-controlled studies, and 8 intensity trials. The primary outcome of the analysis was first major cardiovascular event, including 

Across all 51 trials, a total of 357,440 patients were enrolled in the analysis. Patients had a mean age of 65 years (standard deviation [SD], 9.7), and 41.6% (n = 148,602) were women. Mean baseline BP was 152/87 mmHg. Patients were divided into 10 deciles, with a 14-fold gradient in predicted risk. The total population had a median risk of 12.3% (interquartile range [IQR], 7.6-19).

Among patients in the first decile (<4% predicted risk), mean predicted risk was 3% and the proportion of patients with established cardiovascular disease or diabetes was 11.6% and 11.1%, respectively. In contrast, Decile 10 (>27% predicted risk) saw a mean predicted risk of 41.6%, with a mean age of 72.8 years and a proportion of patients with established cardiovascular disease or diabetes of 55.4% and 53.8%, respectively. However, Rahimi and colleagues noted relatively similar BP between the lowest and highest decile; mean systolic/diastolic BP was 153.5/91.3 mmHg and 158.4/83.2 mmHg, respectively.

Ultimately, Rahimi and colleagues found that intervention, regardless of the form it took, resulted in a significant and consistent reduction in the risk of the primary outcome. Among Decile 1, 1.9% of patients receiving BP-lowering medication experienced a first major cardiovascular event versus 2% of the comparator arm. Decile 10 saw 11.4% of the intervention arm experience the primary outcome, while 13% of comparator recipients had a first major cardiovascular event.

However, Rahimi and colleagues also noted a negligible impact of BP beyond predicted cardiovascular disease risk. While absolute risk reduction increased progressively with baseline predicted risk, it did not substantially increase by BP. Additionally, adverse events, including palpitations, bradycardia, hypotension, end-stage renal disease, and syncope, were more frequent among patients receiving treatment.

Ultimately, Rahimi argues that this study supports an expanded role of risk-based treatment, prioritizing more direct targeting over higher numbers of patients treated. Additionally, while BP is still relevant to determine the potential magnitude of reduction, risk should be the primary decision-making factor over only BP.

“If someone is eligible for treatment, you should try early, and experiment with different strategies,” Rahimi said. “The common practice that we see is to just start with very low-dose treatment and invite the patient to come back a few months later; this, unfortunately, foregoes the opportunity for prevention, and is unlikely to be a good strategy from patients’ perspective.”

Editors’ Note: Rahimi reports disclosures with Medtronic and grants from the UK Research and Innovation, the European Union, and the Medical Research Council.

Rahimi K, Bidel Z, Nazarzadeh M, et al. Blood pressure-lowering treatment across the cardiovascular risk spectrum. Presented at the European Society of Cardiology (ESC) Congress 2026, Munich, Germany. August 28-31, 2026.

Yang, Q., Bidel, Z., Canoy, D. et al. A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials. 

https://doi.org/10.1038/s41591-026-04514-3

Videos

Kazem Rahimi, MD, discusses his recent IPD analysis highlighting the consistent relative risk reduction of first cardiovascular event with BP-lowering drugs.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Professor of Clinical Microbiology at Radbound University Medical Center

The phase 3b ENCORE trial assessing amikacin liposome inhalation suspension (ALIS) added to multidrug therapy in antibiotic-naive adults with newly diagnosed Mycobacterium avium complex lung disease (MACLD) met its primary end point, with significantly greater improvement in respiratory symptoms in the ALIS arm versus comparator at month 13 (

 = .0299), and showed significantly higher rates of culture conversion at months 6, 12, and 13, along with durable culture conversion at month 15 (

ENCORE's decision to use a patient-reported respiratory symptom score, rather than a purely microbiologic measure, as its primary endpoint reflects an FDA requirement, but also a deliberate shift in what the trial was designed to prove, according to Jakko van Ingen, MD, PhD, professor of diagnostics and antimicrobial therapy of mycobacterial infections at Radboud University Medical Center. Van Ingen discussed the trial in an interview with HCPLive about data presented as a late-breaking abstract at the 

2026 European Respiratory Society (ERS) Congress

, held September 5 to 9 in Barcelona, Spain.

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD

Van Ingen said that as a microbiologist, his instinct is to focus on whether the causative bacteria are eliminated, but that outcome is ultimately a means to an end. 

“You do that because you want the person suffering from this terrible disease to improve, to feel better, to be able to live a happy life,” he said, noting that ENCORE tracked whether patients' symptoms improved not only during treatment but through the first 3 months after treatment ended, rather than relying solely on culture status as a proxy for how patients actually felt.

On where ALIS might fit going forward, van Ingen said the trial's design leaves an important caveat: the comparator arm in ENCORE was itself a deviation from current treatment guidelines, meaning the study did not directly compare ALIS against the guideline-recommended first-line regimen. He was candid, however, about how thin the evidence base for that existing first-line regimen actually is, describing it as supported mainly by case series and a single trial still nearing completion, and said there is in fact some evidence that runs counter to that current standard. 

“As a microbiologist, I have to say there's actually evidence that speaks against the regimen that we currently consider to be the first-line treatment regimen. So, in that light, I do see that the the ENCORE trial supports the position of ALIS as part of a first-line multi-drug treatment for earlier stages of non-cavitary MMACLD,” Van Ingen said.

Importantly, the United States Food and Drug Administration (FDA) today granted Priority Review to Insmed's supplemental new drug application (sNDA) for ALIS for full approval for newly diagnosed and recurrently infected MACLD, with a PDUFA target action date of January 28, 2027, based off findings from ENCORE.

van Ingen’s disclosures include Paratek, Insmed, MannKind, and AN2 Therapeutics.

van Ingen J, Van Braeckel E, Feng J, et al. Microbiologic outcomes and recurrence in patients with newly diagnosed Mycobacterium avium complex lung disease (MACLD) in the phase 3b ENCORE trial. Late-breaking abstract presented at: European Respiratory Society (ERS) Congress 2026; September 5-9, 2026; Barcelona, Spain.

Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. 

 2020;56(1):2000535. doi:10.1183/13993003.00535-2020

Johnson V. FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease. September 21, 2026. Article. HCPLive. 

https://www.hcplive.com/view/fda-grants-priority-review-insmed-arikayce-snda-mac-lung-disease

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

Josh D. Woolley, MD, PhD, professor of psychiatry and behavioral sciences, University of California, San Francisco.

 Viewpoint, Josh D. Woolley, MD, PhD, of the University of California, San Francisco, and colleagues proposed the UMBRAA blinding framework for high-dose 

, which uses a multidrug comparator to mask the placebo.¹

Active placebos have historically been rare in psychiatric trials because they add complexity, carry their own adverse events, and may produce therapeutic effects of their own. Dextromethorphan (DXM), 1 candidate comparator, illustrates this risk directly, since its N-methyl-d-aspartate (NMDA) antagonism at dissociative doses has drawn interest as a standalone antidepressant.

“Even though it's an antidepressant, it's a well-characterized antidepressant, and you could still have a differential outcome, even though it has an antidepressant effect,” Woolley told 

 “Having antidepressant effects is not necessarily bad, but an unknown antidepressant effect is problematic.”

Confounding Risk in Psilocybin Trial Comparators, With Josh Woolley, MD, PhD

DXM and Ketamine Illustrate the Confounding Comparator Problem

Woolley said researchers do not typically design studies to prove a drug is not an antidepressant, since disproving a therapeutic effect is difficult to demonstrate. He pointed to ketamine as a further example: investigators have proposed comparing ketamine with psilocybin because participants may confuse the 2 experiences despite differing time courses, with ketamine's effects reported within days and psilocybin's extending across weeks to months.

Woolley contrasted DXM with agents such as zolpidem and niacin, neither of which is considered an antidepressant. He said if a combination of drugs not believed to have antidepressant properties produced a delirium-like state matching high-dose psilocybin's outcomes, the finding would suggest the treatment effect is not pharmacologically specific to psilocybin. Woolley called this scenario a genuinely radical result forcing investigators to rethink how psilocybin works.

UMBRAA's Next Steps: Incomplete Disclosure and Drug Combinations

Why is DXM considered a risky comparator for psilocybin trials?


Its NMDA receptor antagonism at dissociative doses has drawn interest as a standalone antidepressant, so a single high dose could confound trial outcomes with an unknown therapeutic effect.

Is authorized incomplete disclosure a new concept?


No. Woolley traces its lineage to early Johns Hopkins University psilocybin studies in patients with cancer, where participants were told a dose range but not the exact number of trial arms.

What are the next steps for testing UMBRAA?


Woolley said investigators are beginning to test incomplete disclosure directly and plan to evaluate specific multidrug combinations, such as THC and DXM, in healthy volunteers or clinical trials.

Woolley said authorized incomplete disclosure is not new to psychedelic research, citing early studies from Johns Hopkins University in the early 2010s testing psilocybin in patients with cancer. Those studies told participants they would receive psilocybin from within a stated dose range without disclosing the exact number of trial arms, an early form of incomplete disclosure.² Woolley said he and other investigators are now beginning to test the approach directly to determine whether it improves masking success.

A second priority is testing specific multidrug combinations, since limited empirical work has been done despite years of informal discussion. Woolley pointed to tetrahydrocannabinol (THC) and DXM as 1 combination with only preliminary testing. He said this work could proceed in healthy volunteers or within active clinical trials designed to improve outcomes for participants.

Woolley's comments reflect the Viewpoint's central argument: current active placebos do not adequately mask the effects of high-dose psilocybin, leading some investigators to consider comparative efficacy designs instead.¹ Woolley said UMBRAA remains untested and that its authors have not endorsed a single drug combination for all investigators to use.

"I don't want to give up on masking before we've really given it a good try," Woolley said. "Scientists and patients should advocate for that, because they don't want something that waste[s] their time and money [and] puts them at risk without being pretty sure it works."

Watch parts 1, 2, and 3 of the interview with Woolley here: 

UMBRAA Framework Aims to Fix Blinding Failures in Psychedelic Trials

UMBRAA Framework Targets Blinding Failures in Psilocybin Trials

Defending Multidrug Masking in Psilocybin Trials, With Josh Woolley, MD, PhD

Editor’s note: A reported disclosure for Woolley includes Eli Lilly and Company.

Yang KH, Heifets BD, Krystal A, et al. The case for more aggressive masking in psychedelic trials. 

Matvey M, Kelley DP, Bradley ER, Chiong W, O'Donovan A, Woolley J. Modifying informed consent to help address functional unmasking in psychedelic clinical trials. 

Woolley discusses why an active placebo's own therapeutic effects complicate psilocybin trial blinding and outlines next steps for testing UMBRAA.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

PTSD

Confounding Risk in Psilocybin Trial Comparators, With Josh Woolley, MD, PhD 

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.

Hematology

FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Strategic Alliance Partnership

Binge Drinking and ALD, MetALD Fibrosis Risk, With Frances Lee, MD

van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.

ENCORE: Early ALIS Cuts MACLD Recurrence, With Jakko Van Ingen, MD, PhD

In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.

Q&A: Zasocitinib's Role Beyond Topicals in Moderate to Severe Psoriasis

The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.

Infectious Disease

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on viruses, infections, and bacteria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for COVID-19, influenza, vaccine-preventable diseases, and more.

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

An exploratory analysis of the phase 2 EVITA trial found a survival difference, but abnormal cell growth did not change.

Oral Vitamin C Shows Possible Survival Signal in Precancerous Blood Disorders

Biologic evidence in EoE is expanding beyond traditional measures of response. The panel explores how data on esophageal distensibility and pediatric outcomes may refine patient selection and inform clinical decision-making.

Video Series

Evolving Biologic Evidence in EoE

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Anaphylm Is Back at the FDA: A Clinician FAQ on Needle-Free Epinephrine

Long-term EoE management requires evidence that extends beyond initial treatment response. The panel examines 4-year BOS data and what they reveal about durability of response, tolerability, and sustained disease control.

Long-Term Budesonide Oral Suspension Data in EoE

Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Latest News

Q&A: Zasocitinib Response in the Scalp, Nails, Palms and Soles

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

Blood Pressure Treatment Shows Consistent Benefit Across Cardiovascular Risk Spectrum

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD

Confounding Risk in Psilocybin Trial Comparators, With Josh Woolley, MD, PhD